Human 4-1BB-expressing Raji Cells

Human lymphoblast cells - ADCC 4-1BB Target Cells

ABOUT

Human 4-1BB-expressing B cells

Raji-h4-1BB cells were developed from the human Raji cell line, a human B lymphocyte-derived cell line, and engineered to stably overexpress the human 4‑1BB gene. Raji cells have been successfully used as target cells in antibody effector studies such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) assays with peripheral T cell-derived Jurkat reporter cells.

4-1BB (also known as CD137 or TNFSF9) is a co-stimulatory immune checkpoint (IC) receptor that belongs to the tumor necrosis factor receptor (TNFR)/TNF superfamily. 4-1BB is expressed on a multitude of cells including activated CD8+ and CD4+ T cells [1]. Upon 4-1BB binding to its ligand, 4-1BBL (CD137L), expressed on antigen-presenting cells (APCs), NF‑κB‑dependent signaling is activated within the T cell, powerfully augmenting T cell activation, proliferation, and survival [1]. Notably, activation of 4-1BB has the capacity to mediate strong effector T cell immune responses and thus, makes it an attractive target for cancer immunotherapy [1,2]. Despite 4-1BB agonistic antibodies eliciting potent anti-tumor responses, monotherapy progress has been limited in the clinic  [2]. However, combinational therapies may be promising with a significant synergistic effect observed when used in combination with IC inhibitory antibodies (e.g. Anti-CTLA-4 and Anti-PD-1) [1,2].

Features of Raji-h4-1BB cells:

  • Stable overexpression of the human 4-1BB gene
  • Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
  • Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL

Applications for Raji-h4-1BB cells:

Validation of Raji-h4-1BB cells:

  • Overexpression of 4-1BB verified by flow cytometry
  • Functionally tested as target cells in ADCC assays using anti-human 4-1BB mAbs and Jurkat-Lucia™ NFAT-CD16 cells
  • Guaranteed mycoplasma-free

 

References:

1. Bartkowiak, T. & Curran, M.A. 2015. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 5, 117.
2. Ascierto, P.A. et al. 2010. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37, 508-516.

Disclaimer:  These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.

SPECIFICATIONS

Specifications

Species
Human
Tested applications

ADCC/ADCP assays using anti-human 4-1BB mAbs and Jurkat-Lucia™ NFAT-CD16 or CD32 cells

Cell type
Lymphoblastic
Growth properties
Suspension
Tissue origin
Human B cell lymphoma
Antibiotic resistance
Blasticidin
Growth medium

Complete IMDM (see TDS)

Mycoplasma-free

Tested and validated using PlasmotestTM.

Quality control

Each lot is functionally tested and validated.

Expression of human 4-1BB has been verified by flow-cytometry.

Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using anti-h41BB antibodies and InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells reporter cell line.

CONTENTS

Contents

  • Product: 
    Raji-h4-1BB Cells
  • Cat code: 
    raji-h41bb
  • Quantity: 
    3-7 x 10^6 cells
Includes:
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Normocin™ (50 mg/ml)

Shipping & Storage

  • Shipping method:  Dry ice
  • Storage:

    • Liquid nitrogen vapor
    Stability: 20 passages

DOCUMENTS

Documents

Raji-h4-1BB Cells

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?